Markets:

Overview

News

Currencies

International

Treasuries

Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

14.97 -0.46 (-2.98%)

Streaming Delayed Price Updated: 12:01 PM EST, Jan 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Wave Life Sciences Ltd. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Why Cerevel Therapeutics Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

December 07, 2023

Shares of Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE) jumped in pre-market trading after AbbVie Inc. (NYSE: ABBV) announced it will acquire the company for a total equity value of approximately...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 07, 2023

It's time to start off Thursday with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!

Via InvestorPlace

Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares

December 07, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

WAVE Life Sciences's Earnings Outlook ↗

November 08, 2023

Via Benzinga

Earnings Scheduled For August 3, 2023 ↗

August 03, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is likely to report quarterly earnings at $1.10 per share on revenue of $512.74 million.

Via Benzinga

Analyst Ratings for WAVE Life Sciences ↗

June 23, 2023

Via Benzinga

Sprinklr Reports Downbeat Earnings, Joins Chewy, GameStop And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

December 07, 2023

U.S. stock futures traded mixed this morning, with the Dow Jones futures falling around 70 points on Thursday. Shares of Sprinklr, Inc. (NYSE: CXM) shares fell sharply in pre-market trading following...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

December 06, 2023

Via Benzinga

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

December 06, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency

December 06, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference

November 22, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update

November 09, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Earnings Scheduled For November 9, 2023 ↗

November 09, 2023

Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is expected to report quarterly earnings at $0.30 per share on revenue of $265.00 million.

Via Benzinga

Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023

November 03, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day

September 28, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference

September 25, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

2 Cutting-Edge Gene-Editing Stocks That You Don't Want to Miss ↗

September 19, 2023

The gene-editing market is moving fast, and it pays to get to know some of these companies.

Via The Motley Fool

Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

September 06, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

September 05, 2023

Via Benzinga

Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”

September 05, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

7 A-Rated Biotech Stocks for Your August Buy List ↗

August 17, 2023

Investing in biotech stocks means accepting a long R&D window, but the rewards when your A-rated biotech stocks come through are huge.

Via InvestorPlace

Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update

August 03, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023

July 27, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Analyst Creates Bullish Pitch For WAVE Life Sciences, Says It Is 'Leader To Clinic In RNA Editing' ↗

July 05, 2023

Raymond James has initiated coverage on WAVE Life Sciences Ltd (NASDAQ: WVE) with a price target of $9 and

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 ↗

July 05, 2023

Via Benzinga

Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes

June 26, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

Why America's Car-Mart Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

May 24, 2023

Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods.

Via Benzinga

Wave Life Sciences' Stock Falls: Investigational Therapy Fails To Show Clinical Benefit In Rare Neurological Diseases ↗

May 23, 2023

Wave Life Sciences Ltd (NASDAQ: WVE) announced topline results from the Phase 1b/2a FOCUS-C9 study evaluating WVE-004 as an investigational treatment for C9orf72-associated amyotrophic lateral...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

May 23, 2023

Via Benzinga

Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

May 23, 2023

From Wave Life Sciences USA, Inc.

Via GlobeNewswire

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.